“Refiling a provisional is just a bad idea when you can, for a few hundred dollars more, keep hold of that earliest priority date and continue on the path to obtaining a patent.” The question that we ...

Many startup companies are formed around new ideas and inventions. Therefore, protecting such innovations may be extremely important, especially early on. If your business plan includes foreign ...

“Provisional patent applications are widely touted as the go-to thing for startup companies or independent inventors, but they are always the wrong thing to do,” says Russ Krajec, CEO of BlueIron, a ...

Filing a provisional patent application was introduced into U.S. patent law in 1994. The ability to file a provisional application was widely applauded at the time and filing provisional applications ...

“If you cannot get a confidentiality agreement signed you absolutely must file a patent application first, and you really should have professional help doing that if you can afford it.” As mentioned ...

" Filing of this provisional patent application is a step towards securing protection for our delivery platform, which is essential as we progress the design of formulations capable of moving ...

JUPITER, Fla.--(BUSINESS WIRE)--BioCurity, a private preclinical biotech, is developing oncology supportive care drugs that are designed to prevent or mitigate some of the side effects associated with ...

Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines Fresh experimental data expected to strengthen ...

Sources stress the importance of careful drafting after an Australian court rejected the Korean company’s priority claims that were traced back to an unconventional manuscript A Federal Court of ...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative ...

Hoth Therapeutics filed patents to address skin toxicities from cancer therapies, focusing on HT-001's neurogenic and inflammatory pathway targeting. The patents aim to secure intellectual property ...